DE69125175D1 - Verwendung von angiotensin-ii-rezeptorantagonisten bei der behandlung von atheromen - Google Patents

Verwendung von angiotensin-ii-rezeptorantagonisten bei der behandlung von atheromen

Info

Publication number
DE69125175D1
DE69125175D1 DE69125175T DE69125175T DE69125175D1 DE 69125175 D1 DE69125175 D1 DE 69125175D1 DE 69125175 T DE69125175 T DE 69125175T DE 69125175 T DE69125175 T DE 69125175T DE 69125175 D1 DE69125175 D1 DE 69125175D1
Authority
DE
Germany
Prior art keywords
atheroms
angiotensin
treatment
receptor antagonists
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69125175T
Other languages
English (en)
Other versions
DE69125175T2 (de
Inventor
James Hill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Application granted granted Critical
Publication of DE69125175D1 publication Critical patent/DE69125175D1/de
Publication of DE69125175T2 publication Critical patent/DE69125175T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69125175T 1990-12-14 1991-12-12 Verwendung von angiotensin-ii-rezeptorantagonisten bei der behandlung von atheromen Expired - Lifetime DE69125175T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909027201A GB9027201D0 (en) 1990-12-14 1990-12-14 Medicaments
PCT/GB1991/002222 WO1992010184A1 (en) 1990-12-14 1991-12-12 Use of angiotensin ii receptor antagonists in the treatment of atheroma

Publications (2)

Publication Number Publication Date
DE69125175D1 true DE69125175D1 (de) 1997-04-17
DE69125175T2 DE69125175T2 (de) 1997-07-10

Family

ID=10687037

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69125175T Expired - Lifetime DE69125175T2 (de) 1990-12-14 1991-12-12 Verwendung von angiotensin-ii-rezeptorantagonisten bei der behandlung von atheromen

Country Status (6)

Country Link
EP (1) EP0561876B1 (de)
JP (1) JPH06503336A (de)
AU (1) AU9064191A (de)
DE (1) DE69125175T2 (de)
GB (1) GB9027201D0 (de)
WO (1) WO1992010184A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
ATE250587T1 (de) * 1989-06-14 2003-10-15 Smithkline Beecham Corp Imidazoalkensäure
CA2018443A1 (en) * 1989-06-14 1990-12-14 Joseph A. Finkelstein Imidazolyl-alkenoic acids

Also Published As

Publication number Publication date
GB9027201D0 (en) 1991-02-06
WO1992010184A1 (en) 1992-06-25
AU9064191A (en) 1992-07-08
JPH06503336A (ja) 1994-04-14
DE69125175T2 (de) 1997-07-10
EP0561876A1 (de) 1993-09-29
EP0561876B1 (de) 1997-03-12

Similar Documents

Publication Publication Date Title
ATE110556T1 (de) Verbesserungen bei der behandlung von zähnen.
DE69128941D1 (de) Verwendung von angiotensin-ii-rezeptorantagonisten in der behandlung der diabetischen nephropathie
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE69332898D1 (de) 4-Carboxamidopiperidinderivate und ihre Verwendung als Neurokinin Antagonisten
DE69125237D1 (de) Orthopädische Bandage
MX9101311A (es) Antagonistas receptores de fibrinogeno
DE69115182D1 (de) Polymerzusammensetzung und ihre Verwendung.
DE69212620D1 (de) Verwendung von Glycosaminoglycanen zur Behandlung von diabetischer Nephropathie und diabetischer Neuropathie
MX9100717A (es) Antagonistas de la bradiquinina
ATE286510T1 (de) In der behandlung von il4 auslösenden krankheiten nützliche rekombinante il4 antikörper
ATE292975T1 (de) Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii
DE69418203D1 (de) Zementiermittel und ihre verwendung
DE69123178D1 (de) Verwendung von Uridin zur pharmakologischen Behandlung der peripheren Komplikationen bei Diabetes
DE69133390D1 (de) Verwendung von angiotensin-ii-rezeptorantagonisten in der behandlung von hämorragischem schlaganfall
DE69214283D1 (de) Verwendung von cellulase bei der zellstoffbehandlung
DE69125175D1 (de) Verwendung von angiotensin-ii-rezeptorantagonisten bei der behandlung von atheromen
DE69534632T2 (de) Clotrimazol-Metaboliten bei der Behandlung von Sichelzellenkrankheit
NO932391D0 (no) Angiotensin-ii reseptorantagonister for behandling av hjerterytmeforstyrrelser
DE69132782D1 (de) Verwendung von angiotensin-ii-antagonisten in der behandlung der linken ventrikulären hypertrophie
FI925724A (fi) Producering av immunoglobuliner i trichoderma
NO913774L (no) Cykloheksylfenylpyrimidiner, fremgangsmaate for fremstilling og anvendelse derav i vaeskekrystallinske blandinger
MX9102120A (es) Tela
DE69122469D1 (de) Harzzusammensetzung und ihre Verwendung
ATE125534T1 (de) Substituierte dibenzonfurane und ihre verwendung.
DE69328467T2 (de) Polyamidzusammensetzung und Verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition